These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
649 related articles for article (PubMed ID: 25251967)
1. Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion. Weinstock C; Möhle R; Dorn C; Weisel K; Höchsmann B; Schrezenmeier H; Kanz L Transfusion; 2015 Mar; 55(3):605-10. PubMed ID: 25251967 [TBL] [Abstract][Full Text] [Related]
2. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab. Gupta S; Fenves A; Nance ST; Sykes DB; Dzik WS Transfusion; 2015 Mar; 55(3):623-8. PubMed ID: 25257194 [TBL] [Abstract][Full Text] [Related]
3. Discriminating complement-mediated acute transfusion reaction for type O+ red blood cells transfused into a B+ recipient with the complement hemolysis using human erythrocytes (CHUHE) assay. Cunnion KM; Hair PS; Krishna NK; Whitley PH; Goldberg CL; Fadeyi EA; Maes LY Transfusion; 2016 Jul; 56(7):1845-8. PubMed ID: 26997226 [TBL] [Abstract][Full Text] [Related]
4. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes. Sica M; Rondelli T; Ricci P; De Angioletti M; Risitano AM; Notaro R J Hematol Oncol; 2017 Jun; 10(1):126. PubMed ID: 28629435 [TBL] [Abstract][Full Text] [Related]
5. Acute hemolysis of transfused A2 red cells by an auto-HI antibody. Darabi K; Makar RS Transfusion; 2008 May; 48(5):964-8. PubMed ID: 18454737 [TBL] [Abstract][Full Text] [Related]
6. Severe haemolysis and renal failure in a patient with paroxysmal nocturnal haemoglobinuria. Jackson GH; Noble RS; Maung ZT; Main J; Smith SR; Reid MM J Clin Pathol; 1992 Feb; 45(2):176-7. PubMed ID: 1541704 [TBL] [Abstract][Full Text] [Related]
7. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch. Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220 [TBL] [Abstract][Full Text] [Related]
16. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Biglarnia AR; Nilsson B; Nilsson T; von Zur-Mühlen B; Wagner M; Berne C; Wanders A; Magnusson A; Tufveson G Transpl Int; 2011 Aug; 24(8):e61-6. PubMed ID: 21696455 [TBL] [Abstract][Full Text] [Related]
17. Severe hemolytic anemia due to multiple red cell alloantibodies after an ABO-incompatible allogeneic bone marrow transplant. López A; de la Rubia J; Arriaga F; Jiménez C; Sanz GF; Carpio N; Marty ML Transfusion; 1998 Mar; 38(3):247-51. PubMed ID: 9563404 [TBL] [Abstract][Full Text] [Related]
18. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Risitano AM; Notaro R; Marando L; Serio B; Ranaldi D; Seneca E; Ricci P; Alfinito F; Camera A; Gianfaldoni G; Amendola A; Boschetti C; Di Bona E; Fratellanza G; Barbano F; Rodeghiero F; Zanella A; Iori AP; Selleri C; Luzzatto L; Rotoli B Blood; 2009 Apr; 113(17):4094-100. PubMed ID: 19179465 [TBL] [Abstract][Full Text] [Related]
19. Complement receptor 1 inhibitors for prevention of immune-mediated red cell destruction: potential use in transfusion therapy. Yazdanbakhsh K; Kang S; Tamasauskas D; Sung D; Scaradavou A Blood; 2003 Jun; 101(12):5046-52. PubMed ID: 12576307 [TBL] [Abstract][Full Text] [Related]